Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug

Premium

Alnylam Pharmaceuticals this week announced that it has started a phase I trial of its subcutaneous TTR-mediated amyloidosis treatment ALN-TTRsc.

The study is being conducted in the UK and will examine single and multiple escalating doses of the drug in up to 40 healthy volunteers.

The trial’s primary endpoints are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum levels of the TTR protein. Data is expected to be available by mid-year, Alnylam said.

As previously disclosed, a phase II trial of ALN-TTRsc is slated to begin before the end of 2013, with a pivotal trial on track for 2014.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.